Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 17/20 | 0.67 |
| ▸ | CDK7 | P50613 | 4/20 | 0.67 |
| ▸ | CDK9 | P50750 | 4/20 | 0.67 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.67 |
| ▸ | CLK1 | P49759 | 1/20 | 0.57 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.57 |
| ▸ | CDK4 | P11802 | 9/20 | 0.49 |
| ▸ | AURKA | O14965 | 5/20 | 0.49 |
| ▸ | CDK1 | P06493 | 4/20 | 0.49 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.49 |
| ▸ | PLK1 | P53350 | 3/20 | 0.48 |
| ▸ | IKBKB | O14920 | 2/20 | 0.48 |
| ▸ | GSK3B | P49841 | 2/20 | 0.48 |
| ▸ | CDC7 | O00311 | 1/20 | 0.48 |
| ▸ | PLK4 | O00444 | 1/20 | 0.48 |
| ▸ | CHUK | O15111 | 1/20 | 0.48 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.48 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.48 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.48 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2087388 | 0.88 | CDK2 (0.67) | CDK2CDK7CDK9CCNT1CLK1 | |
| SCHEMBL2086279 | 0.88 | CDK2 (0.67) | CDK2CDK7CDK9CCNT1CLK1 | |
| SCHEMBL2085816 | 0.88 | CDK2 (0.67) | CDK2CDK7CDK9CCNT1CLK1 | |
| SCHEMBL2086410 | 0.88 | CDK2 (0.67) | CDK2CDK7CDK9CCNT1CLK1 | |
| SCHEMBL2086427 | 0.86 | CDK2 (0.60) | CDK2CDK7CDK9CCNT1CLK1 | |
| SCHEMBL2087319 | 0.86 | MKNK2 (0.72) | CDK2CDK7CDK9CCNT1CLK1 | |
| SCHEMBL2084979 | 0.86 | CDK2 (0.65) | CDK2CDK7CDK9CCNT1CLK1 | |
| SCHEMBL2084860 | 0.85 | CDK2 (0.64) | CDK2CDK7CDK9CCNT1CLK1 | |
| SCHEMBL2084100 | 0.84 | CDK2 (0.60) | CDK2CDK7CDK9CCNT1CLK1 | |
| SCHEMBL5475117 | 0.84 | CDK2 (0.57) | CDK2CDK7CDK9CCNT1CLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1678171-B1 | 2-AMINO-4-THIAZOLONE-PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LTD (GB) | 2016-09-14 | — | — | EP | claimed |
| US-7902361-B2 | Pyrimidin-4-yl-3, 4-thione compounds and their use in therapy | CYCLACEL LIMITED (GB) | 2011-03-08 | — | — | US | claimed |
| US-7427627-B2 | N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl)-N-phenylamines as antiproliferative compounds | CYCLACEL LIMITED (GB) | 2008-09-23 | — | — | US | claimed |
| EP-1951307-A2 | COMBINATION OF A CDK-INHIBITOR AND A HDAC-INHIBITOR | Cyclacel Limited (GB) | 2008-08-06 | — | — | EP | claimed |
| WO-2007054725-A2 | COMBINATION OF A CDK-INHIBITOR AND A HDAC-INHIBITOR | CYCLACEL LIMITED (GB) | 2007-05-18 | — | — | WO | claimed |
| JP-2007509117-A | — | — | 2007-04-12 | — | — | JP | claimed |
| US-20070021452-A1 | Pyrimidin-4-YL-3, 4-thione compounds and their use in therapy | CYCLACEL LIMITED (GB) | 2007-01-25 | — | — | US | claimed |
| US-20060199830-A1 | N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl)-N-phenylamines as antiproliferative compounds | CYCLACEL LIMITED (GB) | 2006-09-07 | — | — | US | claimed |
| EP-1678171-A1 | PYRIMIDIN-4-YL-3,4-THIONE COMPOUNDS AND THEIR USE IN THERAPY | Cyclacel Limited (GB) | 2006-07-12 | — | — | EP | claimed |
| US-20050288307-A1 | Anti-viral compounds | CYCLACEL LIMITED (GB) | 2005-12-29 | — | — | US | claimed |
| WO-2005042525-A1 | PYRIMIDIN-4-YL-3, 4-THIONE COMPOUNDS AND THEIR USE IN THERAPY | CYCLACEL LIMITED (GB) | 2005-05-12 | — | — | WO | claimed |
| EP-1678171-B1 | 2-AMINO-4-THIAZOLONE-PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LTD (GB) | 2016-09-14 | — | — | EP | disclosed |
| US-7902361-B2 | Pyrimidin-4-yl-3, 4-thione compounds and their use in therapy | CYCLACEL LIMITED (GB) | 2011-03-08 | — | — | US | disclosed |
| US-7427627-B2 | N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl)-N-phenylamines as antiproliferative compounds | CYCLACEL LIMITED (GB) | 2008-09-23 | — | — | US | disclosed |
| US-7427627-B2 | N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl)-N-phenylamines as antiproliferative compounds | CYCLACEL LIMITED (GB) | 2008-09-23 | — | — | US | disclosed |
| EP-1678171-A1 | PYRIMIDIN-4-YL-3,4-THIONE COMPOUNDS AND THEIR USE IN THERAPY | Cyclacel Limited (GB) | 2006-07-12 | — | — | EP | disclosed |
| US-20050288307-A1 | Anti-viral compounds | CYCLACEL LIMITED (GB) | 2005-12-29 | — | — | US | disclosed |
| EP-1581231-A1 | ANTI-VIRAL COMPOUNDS | Cyclacel Limited (GB) | 2005-10-05 | — | — | EP | disclosed |
| WO-2005042525-A1 | PYRIMIDIN-4-YL-3, 4-THIONE COMPOUNDS AND THEIR USE IN THERAPY | CYCLACEL LIMITED (GB) | 2005-05-12 | — | — | WO | disclosed |
| WO-2004043467-A1 | ANTI-VIRAL COMPOUNDS | CYCLACEL LIMITED (GB) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021452-A1 | Pyrimidin-4-YL-3, 4-thione compounds and their use in therapy | MSRB3, DHFR, CBR3 | CDK2 459/4885CDK7 1077/4885CDK9 1001/4885 |
| US-20060199830-A1 | N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl)-N-phenylamines as antiproliferative compounds | CDK4, CDK2, CCNI | CDK2 2/4885CDK7 8/4885CDK9 10/4885 |
| US-20050288307-A1 | Anti-viral compounds | MAVS, HAVCR2, EIF2AK2 | CDK2 205/4885CDK7 664/4885CDK9 855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.